This  EHA Clinical Practice Guideline addresses the critical role of PET-CT imaging in risk stratification, staging, and response assessment, while outlining first-line treatment strategies, including the role of R-CHOP and Pola-R-CHP. It also addresses tailored approaches for

ZRSR2 loss causes aberrant splicing in JAK2V617F-driven myeloproliferative neoplasm but is not sufficient to drive disease progression 📰 https://t.co/aH867c82B8 @Sci_Ranran

This paper reports that patients with relapsed or refractory follicular lymphoma treated with varnimcabtagene autoleucel achieved high response rates and durable disease control, with manageable side effects and prolonged CAR T-cell persistence. #R/RFL 🚨 https://t.co/c7ac1qowdT

🎧 Inspirational interview from EHA Unplugged with our own Editor in Chief of HemaSphere Prof Jan Cools, who received the EHA 2025 Education & Mentoring Award. Prof Cools describes his approach to mentoring students and scientists, emphasizing the aspects that he finds most

This paper shows that switching elranatamab dosing from weekly to every two weeks did not worsen patient-reported quality of life in relapsed/refractory multiple myeloma. Authors found most symptoms and side effects remained stable for over a year. Read more here

Our October issue is now open and live! Find the the most recent clinical, translational and basic #hematology research, always open access and with continuous publication.  🔓 https://t.co/DfyavEwN2f

Curious about the best first, second, or third-line treatments for large B-cell lymphoma (LBCL)? Browse the newly published #EHAGuidelines in @Hemasphere_EHA, our open access scientific journal. Prepared by a selection of cross-disciplinary experts, these guidelines focus on: ✅

This recently published paper reports that children with T-cell acute lymphoblastic leukemia in the AIEOP-BFM ALL 2009 trial had favorable outcomes. The authors highlight that early MRD levels, CNS involvement and prednisone response are important for risk assessment and

This Editorial highlights how collaboration and mutual support between researchers helped advance understanding of CLL biology, leading to better prognostic tools and new therapies.  Relationships and perseverance are vital in scientific progress, hidden skills not often

Our September issue is now complete!   Find the latest #hematology research, always open access 🔓 https://t.co/G8mYcJqJUS

This recent study underscores the pronounced elevation of HO-1 levels in pediatric SCD patients, indicating its potential protective role against heme-induced toxicity during childhood. This finding emphasizes the importance of monitoring and managing HO-1 levels in young

🐾 Happy World Animal Day, or Dierendag here in the Netherlands! 🐶🐱🐰🐦🐢 Celebrate the love and joy our furry, feathered, and scaly friends bring into our lives! 🌍❤️ Our pets help us while we review, edit, write, and publish, and at least here at HemaSphere also like to join

🎙️New Podcast Episode! Join our host HemaSphere Scientific Editor Dr Charles de Bock as he chats with Dr Kai Rejeski, first author of this 2025 HemaSphere Top Cited – Clinical Award-winning paper, "An International Survey on Grading, Diagnosis, and Management of Immune Effector

Gamma delta (γδ) T cells, constituting 5%–10% of peripheral blood lymphocytes, are pivotal in tumor immunosurveillance and are enriched in epithelial tissues. Their unique antigen recognition makes them ideal for allogeneic cell therapy products, with several clinical trials

Arsenic trioxide reprograms bone marrow microenvironment to eliminate #MRD in #AML, an old dog learns new tricks. Read more in our recent issue👉 https://t.co/Bgtxv9BTZT

The European Myeloma Network's guidelines on VTE prevention and treatment in multiple myeloma patients offer evidence-based recommendations. Implementing these guidelines can enhance clinical outcomes and quality of life by reducing morbidity, mortality, and treatment

Chronic lymphocytic leukemia (CLL) cells reprogram their tumor microenvironment (TME) to promote drug resistance and tumor progression. Authors 3D approach reveals that CLL B cells upregulate the AP-1 transcription factor, conferring protection against therapy-induced cell death.

Arsenic trioxide reprograms bone marrow microenvironment to eliminate #MRD in #AML, an old dog learns new tricks. Read more in our recent issue👉 https://t.co/uSKLRGQm4Q

The novel B-CAP regimen has proven to be a feasible and effective first-line treatment for older patients with advanced-stage classic Hodgkin lymphoma. It results in high response rates, favorable 3-year progression-free survival, and sustained improvement in health-related

Our newest episode drops in a few days! Subscribers get early access, so make sure you're subscribed on your favorite platform. This episode is the second of two highlighting the 2025 HemaSphere Award Top Cited - Biology and Clinical from #EHA2025 in Milan.  Join us, the